Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc(ALNY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$143.82
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ALNY

11/20/2026: ALNY (1-star) is currently NOT-A-BUY. Pass it for now.

Alnylam Pharmaceuticals is a commercial-stage biotechnology enterprise pioneering RNA interference (RNAi) therapeutics to treat rare and genetically defined diseases. The company exhibits strong operational execution, backed by a validated proprietary delivery platform and a growing portfolio of approved specialty drugs such as Amvuttra and Onpattro. Its primary growth narrative centers on expanding label indications into high-prevalence cardiovascular conditions like ATTR cardiomyopathy. However, risks remain regarding high R&D reinvestment requirements, intensive competitive pressures from alternative genetic modalities, and complex global reimbursement hurdles. The stock suits growth-oriented investors willing to navigate biotechnology sector volatility while monitoring clinical trial readouts and regulatory milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitAlnylam offers robust top-line product revenue growth driven by an expanding portfolio of rare disease therapies.
Momentum investorMixed fitMomentum fit is conditional on positive near-term clinical readouts and regulatory catalysts.
Value investorWeak fitThe company trades at high valuation multiples based on future growth expectations rather than current earnings.
Dividend investorWeak fitAlnylam does not pay dividends, prioritizing capital reinvestment for pipeline expansion.
Low-risk investorWeak fitBiotechnology sector volatility and clinical trial execution risks present higher risk profiles unsuited for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks frequently experience sharp price movements driven by binary clinical trial results and regulatory decisions.
Valuation riskMedium / highHigh expectations are priced into shares, leaving little margin for error if clinical or commercial milestones slip.
Competition risk (Antisense and gene-editing competition)Medium / highRapid advancements by competitors using alternative genetic platforms threaten long-term market share.
Business qualityStrongAlnylam possesses a leading intellectual property portfolio and validated commercial franchise in RNAi therapeutics.
Dividend incomeLow / noneNo dividend is paid, offering zero income return for investors.
Execution riskHighSuccess relies heavily on timely clinical trial readouts, regulatory approvals, and global commercial execution.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 19.80B USD
Price to earnings Ratio 7.47
1Y Target Price 284.96
Price to earnings Ratio 7.47
1Y Target Price 284.96
Volume (30-day avg) 2.8M shares
Beta 0.44
52 Weeks Range 143.40 - 479.79
Updated Date 11/20/2026
52 Weeks Range 143.40 - 479.79
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) 19.8

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
44.7%
Active BUY / eligible
17 / 38
30-Day BUY Count Change
+9

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 68.96%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ALNY receives a 4-star rating, supported by solid unit economics, solid company fundamentals, solid quantitative characteristics, and strong analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ALNY has solid overall fundamentals (4 stars), with solid financial health, strong growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+212.8%) and solid cash generation (FCF margin 12.5%) are partially offset by soft profitability (net margin 8.4%), very low insider ownership of 0.20%.

Financial Health Rating

★★★★★
ALNY's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 52.0%). Profitability is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is ALNY's strongest growth driver at +1192.7% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+65.2%, strong) and earnings growth (+212.8%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 105.7% and approximately 99.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.20%, which materially reduces the ownership score.

Top 5 Institutional Investors

FMR Inc 11.22%
Capital World Investors 8.32%
Capital Research Global Investors 8.17%
BlackRock Inc 8.14%
Vanguard Portfolio Management, LLC 4.88%

Unit Economics (Per $1K Revenue)

★★★★★
ALNY generates approximately $818 of gross profit, $135 of operating income, and $125 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.91%

Quantitative Style Profile

★★★★★
ALNY has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Product SalesDirect commercial sales of approved RNAi medicines including Amvuttra, Onpattro, Givlaari, and Oxlumo.This is the core engine driving Alnylam's top-line revenue growth.
Collaborations and RoyaltiesMilestone payments, research funding, and royalties from partners like Novartis for partnered drugs such as Leqvio.Provides non-dilutive capital and validation from major pharmaceutical entities.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When Before Market
Estimate 1.46
Actual 15.72

Profitability

Profit Margin 52.85%
Operating Margin (TTM) 19.5%

Management Effectiveness

Return on Assets (TTM) 9.51%
Return on Equity (TTM) 138.07%

Valuation

Trailing PE 7.47
Forward PE 11.68
Enterprise Value 17.69B
Price to Sales(TTM) 3.95
Enterprise Value 17.69B
Price to Sales(TTM) 3.95
Enterprise Value to Revenue 3.53
Enterprise Value to EBITDA 15.54
Shares Outstanding 133.94M
Shares Floating 133.64M
Shares Outstanding 133.94M
Shares Floating 133.64M
Percent Insiders 0.2
Percent Institutions 105.73

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.